What it is
Whether routine invasive management improves long-term survival in chronic coronary disease, when added to guideline-directed medical therapy, has been unknown. The ISCHEMIA trial randomized patients with chronic coronary disease and moderate or severe ischemia, at 320 sites in 37 countries from August 2012, to an initial invasive strategy (medical therapy plus coronary angiography and revascularization when feasible) or an initial conservative strategy (medical therapy alone, with invasive management if it failed); this extended follow-up ran through December 2025 and was analysed by intention to treat. Among 5179 participants, 1071 deaths occurred over a median follow-up of 9 years. All-cause mortality at 11 years was 25.8% with the invasive strategy against 26.9% with the conservative one, not a significant difference (adjusted hazard ratio 0.97, 95% CI 0.86-1.09). Cardiovascular mortality was 15.8% against 17.1% and noncardiovascular mortality 9.1% against 8.1%, neither difference significant.
Why it matters
In stable coronary disease with moderate or severe ischemia, starting with medical therapy alone showed no significant survival difference over a decade. By bayesian analysis the probability that the invasive strategy adds more than 1 percentage point of survival was low (18%), and 11-year restricted mean survival (average time alive over the period) differed by an estimated 14 days, not a significant difference.
Underlined numbers link to their source. Every metric and quoted figure is listed under Sources and data below.
Filed underCoronary Interventions and Diagnostics, Cardiac Imaging and Diagnostics, Acute Myocardial Infarction Research